The global market for cancer profiling technologies should grow from $45.2 billion in 2018 to $90.6 billion by 2023 with a compound annual growth rate (CAGR) of 14.9% for the period of 2018-2023.
Report Scope:
Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.
Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.
The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.
This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also examines recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.
Report Includes:
- 91 tables
- An overview of the global market for cancer profiling and pathways
- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of products in this market, newly emerging tools, diagnostics and therapeutics, and their impacts on the market
- Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
- Identification of important cancer profiling techniques, market shares by types of products on the market, and market shares by company, as well as types of cancers and biomarkers
- Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials and currently marketed, and clinical-stage development products
- Company profiles of key players in the market
Summary
The global healthcare industry is undergoing key developments, advanced point-of-care diagnostics, availability of cost-effective treatment modalities and personalized medicine, which not only offers efficient early stage diagnosis, while also treating cancer conditions in order to reduce the overall healthcare cost and disease burden. This is one technology which has the potential to revolutionize cancer therapeutics and diagnostics in the healthcare sector.
An effective management and administration of targeted therapeutics and monitoring of cancer condition requires frequent profiling of patient’s tumor mutations. Currently, the profiling of cancer has become very critical for cancer diagnosis, clinical trials, research and drug development efforts. With the launch of novel and efficacious targeted therapies that are developed and approved, profiling of tumors will become essential for therapy, patient selection and monitoring.
It is critical to understand the multivariate nature of cancer is and drug response also depends on molecular profiling at genetic, epigenetic and protein levels. Biomarkers, as defined by the National Institutes of Health (NIH), are “characteristics that are objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” A biomarker has to be reliable, measurable, specific and predicative.
Cancer is a highly heterogenous disease involving dysregulation of multiple pathways regulating many fundamental cell processes such as growth, death, proliferation, differentiation and migration. Minor differences and subtle feedback nuances such as tumor microenvironments and endocrine feedback loops, often translate into major differences between cancers, and between patients who have the same cancers. These activities of molecular networks that orchestrate metabolic or cytoskeletal processes, or harmonize these by signal transduction, are altered in a complex manner by many genetic mutations in concert with the environmental context. The challenge is to understand these multivariate dysregulations, with respect to both to how it arises from diverse genetic mutations and to how it can be treated. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues.
The major causes of cancer are infection and chronic inflammation. In this report, a general overview of the connection between cancer profiling technologies and cancer is provided. A better insight of these connections can yield novel diagnostic, preventive, and therapeutic strategies to reduce the global cancer burden. Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Newer and improved methods for microarray analysis, multiplex PCR and quantitative real-time PCR are integral to deciphering the molecular mechanisms involved in gene function, cancer development and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Innovative tools and techniques for sequencing and tumor profiling are growing and may represent excellent opportunities for life science suppliers.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing the Study
Scope of Report
Intended Audience
Methodology
Information Sources
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Cancer Profiling and Pathways
Chapter 3 Overview
Introduction
Biomarkers
Guidelines
Screening Tests
Early Detection and Diagnosis of Cancer
Pathway Profiling
Linking Cancer Disease through Pathway Profiling
Molecular Profiling
Historical Facts
Molecular Profiles
Cancer Profiling
Challenges
Clinical Utility of Molecular Profiling
Pathological Classification
Molecular Profiling Approaches
Cancer Profiling: Future Goals
Chapter 4 Current Profiling Techniques
Genomics
Genomic Profiling
Microarrays
Comparative Genomic Hybridization (CGH)
Key Companies
Key Players
Microarrays to Clinical Problems
Single Nucleotide Polymorphism (SNP)
Multi-color FISH
Companies
DNA Sequencing
Emerging DNA Sequencing Technologies
High-throughput Sequencing
Other Sequencing Technologies
Cancer Applications
Next-Gen Sequencing
Next-Generation Companies
ABI/SOLiD
Other Methods
Patents and Sequencing
Summary
Next-Generation Sequencing Technologies
Next-Generation Sequencing: Future
Genomics and Cancer—Some Examples
Mutations Predicting Resistance to Targeted Therapies
Sequencing and the Clinic
Transcriptomic Profiling
Microarray-based Gene Expression Profiling
Tiling Arrays
qRT-PCR
Cancer Applications
Emerging Microarray Technologies
Future
Chapter 5 Epigenomic Profiling
Overview and Introduction to the Epigenetics Landscape
Cancer Applications
DNA Methylation
microRNA
Epigenetic Changes and Cancer Stem Cells
Epigenetic Therapy for Cancer
Leading Epigenetic Companies
Epigenetics and MicroRNA Profiling—Finding Pathways to Treatment
MicroRNAs and Therapeutic Applications in Cancer
MicroRNAs as Prognostic and Therapeutic Biomarkers
Anti-Cancer Drugs and microRNA Targets
Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
Diagnostic and Therapeutic microRNA Strategies in Cancer
Therapeutic Potential
Therapeutic Strategies
MicroRNAs in Disease Diagnostics
Circulating microRNAs
MicroRNA Profiling Methods
Clinical microRNA Diagnostics
MicroRNAs in Therapeutics
MicroRNA Patents and Outlook
Future
Methylation Markers
DNA Methylation, an Epigenetic Process
Current Methods and Products
Clinical Implications
Future Directions
Epigenetic Diagnostic Development
Epigenetic Drugs
HDAC Inhibitors
Epigenetic Therapeutic Development
Key Players
Chapter 6 Proteomics
Proteomics and Protein Profiling
Proteomics Protein Profiling Approaches
Techniques
Applications of Proteomic Techniques in Cancer Research
Technologies and Limitations
Proteomics and Initiatives
Cancer Applications
Proteomics in the Treatment of Cancer
Clinical Applications of Proteomics
Proteomic Approaches in Therapeutic Targets
Key Players
Proteomics-Based Diagnostic Products
Proteomic Research Centers
Clinical Trial Using Proteomics Technologies for Personalized Medicine
Proteomics and Medicine
Proteomics Market
Chapter 7 Glycomics
What is Glycomics?
Techniques
Analytical High-Throughput Technologies
Emergence of Glycoarrays
Glycoinformatics
Biomedical Applications
Glycomics’s Relationship with Other “Omics” Technologies
Glycomics for Biomarker Discovery
Cancer and Glycomics
Glycomics-Biomarkers for Ovarian Cancer
U.S. Patents on Glycomics
Chapter 8 Metabolomics
What is Metabolomics?
Metabolome
Techniques
Detection Methods
Metabolomics and Drug Discovery
Biomarker Identification
Chapter 9 Bioinformatics, Databases and Pathway Analysis
Chapter 10 Cancer Profiling and Clinical Development
Biomarkers
Cancer and Biomarkers
Chapter 11 Market
Global DNA Diagnostics Market
The Cancer Diagnostics Market
Cancer Diagnostic Tests
The Cancer/Tumor Profiling Market
Personalized Medicine
Cancer Biomarker Testing Market
Genomics Market
SNP Genotyping and Analysis Market
Microarray/Biochips Market
Diagnostic Microarrays
DNA Sequencing Market
PCR Market
Epigenetics and Market
miRNA Market
Epigenetics and Cancer Market and Future Growth
Proteomics in the Pharma Industry
Protein Microarrays and Trends
The Metabolomics Market
Future
Conclusion
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
Best quality reports based on various authentic and accurate data findings.
Your personal and confidential information is safe and secure.
Trends Market Research © Copyright 2021. All Rights Reserved.